Docoh
Loading...

USAQ USA Equities

Filed: 29 Jun 21, 7:30am

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): June 29, 2021

 

USA EQUITIES CORP.

(Exact Name of Registrant as Specified in its Charter)

 

0-19041

(Commission File No.)

 

Delaware 30-1104301

(State

of Incorporation)

 

(I.R.S. Employer

Identification No.)

   

901 Northpoint Parkway Suite 302 West Palm Beach

FL 33407

 33407
(Address of Principal Executive Offices) (ZIP Code)

 

Registrant’s telephone number, including area code: (929) 379-6503

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ]Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
[  ]Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
[  ]Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
[  ]Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.0001 par value USAQ OTCMKTS

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On June 29, 2021, USA Equities Corp. (the “Company”) issued a press release entitled “USA Equities Corp Announces the signing of a Distribution Agreement with a Prominent Physician Management Services Firm For its AllergiEnd® Products and Services.”

 

A copy of the above-mentioned press release is attached herewith as Exhibit 99.1.

 

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The Company uses, and will continue to use, its website (https://usaqcorp.com), press releases, and various social media channels, including its Twitter account (https://twitter.com/USAQcorp), its LinkedIn account (https://www.linkedin.com/company/usaqcorp) its Facebook account (https://www.facebook.com/USA-Equities-100113722270622), and its Instagram account (https://www.instagram.com/usaqcorp/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information that the Company posts on its website, disseminated in press releases and on social media could be deemed to be material information, and the Company encourages investors, the media and others interested in the Company to review the business and financial information that the Company posts on its website, disseminates in press releases and on the social media channels identified above, as such information could be deemed to be material information.

 

ITEM 9.01 Financial Statements and Exhibits

 

Exhibit No. Description
99.1 Press release dated June 29, 2021 entitled “USA Equities Corp Announces the signing of a Distribution Agreement with a Prominent Physician Management Services Firm For its AllergiEnd® Products and Services.”

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: June 29, 2021 
   
USA Equities Corp. 
   
 /s/ Troy Grogan 
Name:Troy Grogan 
Title:CEO and Chairman